Keyphrases
Disease Progression
100%
Multiple Sclerosis
100%
Daclizumab
100%
Anti-CD25 Antibody
100%
Inflammation Inhibition
100%
Interferon-β (IFN-β)
40%
Monotherapy
31%
Combination Therapy
18%
Contrast-enhancing Lesions
18%
Clinical Disability
13%
High Dose
9%
Therapeutic Response
9%
Disease Activity
9%
Brain Magnetic Resonance Imaging
9%
Maryland
4%
Lack of Response
4%
Neurological Disorders
4%
Natural Killer Cells
4%
Phase II Clinical Trial
4%
CD56
4%
Adverse Effects
4%
Inhibition Rate
4%
Suboptimal Response
4%
Therapeutic Effect
4%
Long-term Efficacy
4%
CD8+ T Cells
4%
Intravenous Infusion
4%
Patient Samples
4%
Therapy Effect
4%
Systemic Side Effects
4%
Multiple Sclerosis Treatment
4%
Bethesda
4%
Treatment Phase
4%
Immunological Biomarkers
4%
Neuroimmunology
4%
Interferon-β Treatment
4%
Multiple Sclerosis Exacerbation
4%
Persistent Disease Activity
4%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
100%
Inflammation
100%
Multiple Sclerosis
100%
Daclizumab
100%
Beta Interferon
45%
Monotherapy
31%
Biological Marker
18%
Combination Therapy
18%
Disease Activity
13%
Adverse Event
9%
Clinical Trial
4%
Neurologic Disease
4%
CD8 Antigen
4%
Therapeutic Effect
4%
Neuroscience
Multiple Sclerosis
100%
Daclizumab
100%
Beta Interferon
45%
Magnetic Resonance Imaging
9%
Adverse Effect
9%
T Cell
4%
Neurological Disorder
4%
Natural Killer Cell
4%
CD8
4%
Neuroimmunology
4%